These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 12888585

  • 1. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A, Forsthuber S, Graninger W, Georgopoulos A.
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW, Brown SD.
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE, Brown S, Felmingham D.
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [Abstract] [Full Text] [Related]

  • 7. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C, Marin ME, Quiñones F, Sifuentes-Osornio J, Siller CC, Castanheira M, Zoccoli CM, López H, Súcari A, Rossi F, Angulo GB, Segura AJ, Starling C, Mimica I, Felmingham D.
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [Abstract] [Full Text] [Related]

  • 8. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
    Gómez-Garcés JL, Alós JI, Hernáiz C, Gómez C.
    Enferm Infecc Microbiol Clin; 2004 Feb; 22(6):323-7. PubMed ID: 15228898
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
    Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN.
    Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.